March 5, 2008

News Release

For Immediate Release

THE JENEX CORPORATION ISSUES STATUS REPORT ON  FINANCING

Burlington, Ontario – The Jenex Corporation (“Jenex” or the “Corporation”) TSX Venture Exchange: JEN, Frankfurt: JNX) reports the private placement the Corporation announced in a press release dated December 3, 2007 amended to close by February 29, 2008 has expired.  Management is reviewing current market and Corporate progress in preparation for a new financing placement to be annouced.  The Corporation will be issuing a “Corporate Progress report” in the near future.

About The Jenex Corporation

Jenex has a non-invasive Medical Device that prevents cold sore outbreaks. The interceptCS(TM) Cold Sore Prevention System is approved in Canada and has received CE approval for European Union countries.

In addition to interceptCS, Jenex markets Therapik(R) for insect stings & different insects. Therapik is approved in Canada and the United States and Australia, as well as having CE Mark approval in the European Union countries.  Jenex's Thermal Therapy technology is patented in the U.S, Canada, Australia, & Europe.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release.  Certain information included in this press release is forward-looking and is subject to important risks and uncertainties.  The results or events predicted in these statements may differ materially from actual results or events. 

More information about the Corporation can be found at:

The Jenex Corporation

207 – 940 Sheldon Court

Burlington, Ontario

L7L 5K6

Michael A. Jenkins, President

Telephone: (905) 632-3830

Facsimile: (905) 632-3774

Email: jenex@jenexcorp.com

            www.jenexcorp.com